BASF Faces Crucial Turnaround Phase as Recovery Timeline Extends

BASF sees recovery delayed until 2027, cuts costs and jobs as EBITDA guidance misses estimates. Restructuring accelerates with portfolio changes and a strategic shift to Asia.

The German chemical giant BASF is navigating a challenging transitional period, with company leadership indicating that a meaningful recovery is unlikely before late 2026, and more probably in 2027. In response to this prolonged outlook, the DAX-listed corporation is implementing deeper cost-cutting measures that will significantly impact its workforce.

Financial Targets Fall Short of Market Expectations

For the current fiscal year, BASF has provided EBITDA guidance, excluding special items, in a range of €6.2 to €7.0 billion. The midpoint of this forecast, €6.6 billion, sits notably below the consensus analyst estimate of approximately €7.0 billion. Further pressure stems from currency fluctuations; the relative weakness of the U.S. dollar is projected to negatively affect operating results by as much as €200 million in the first quarter alone. The company also reported that sales volumes in January remained subdued outside of China.

Management's free cash flow projection for the year is between €1.5 and €2.3 billion. This goal highlights a persistent concern: in the previous year, the group generated only €1.34 billion in free cash flow—an amount insufficient to fully cover the dividend payment of €2.25 per share through internally generated funds.

Accelerated Restructuring and Portfolio Reshaping

The company's restructuring initiative is showing tangible results. By the end of 2025, BASF had achieved annual cost savings of €1.7 billion. It has now set a more ambitious target of €2.3 billion in annual savings by the close of 2026.

Achieving these savings comes at a human cost. Since late 2023, 4,800 positions have been eliminated, with additional reductions planned in administrative and IT functions. The company is also relocating certain roles to lower-cost centers in India and Malaysia. Capital expenditure for the period 2026 through 2029 has been slashed by 20%, down to €13 billion.

Concurrently, BASF is actively reshaping its business portfolio. The divestment of its optical brighteners unit is complete, and the sale of the coatings division is slated for the second quarter. Preparations are underway for a potential initial public offering of its agricultural solutions business by 2027. Alongside these divestments, the firm continues its share buyback program, having repurchased 14 million of its own shares since November 2025.

Strategic Balancing Act Between Europe and Asia

BASF's Ludwigshafen site, one of Europe's most energy-intensive industrial complexes, continues to face margin pressure from elevated electricity and natural gas prices, particularly in its basic chemicals operations.

In contrast, the new integrated production site in Zhanjiang, China, is now operational, with its core plants running. However, this expansion faces headwinds from falling prices and substantial overcapacity within the Chinese domestic market.

All eyes are now on the Annual Shareholders' Meeting in Mannheim on April 30. The executive board will need to demonstrate whether the accelerated cost-cutting program can effectively offset structural weaknesses in the core business until a genuine market recovery finally takes hold.